» Articles » PMID: 11686321

The Defective Down Regulation of Fibrinolysis in Haemophilia A Can Be Restored by Increasing the TAFI Plasma Concentration

Overview
Journal Thromb Haemost
Publisher Thieme
Date 2001 Nov 1
PMID 11686321
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

TAFI (thrombin activatable fibrinolysis inhibitor) down regulates fibrinolysis after activation by relatively high concentrations of thrombin generated during coagulation via thrombin mediated factor XI activation and subsequent activation of the intrinsic pathway. It is this secondary burst of thrombin that is severely diminished in haemophilia A, a deficiency of coagulation factor VIII. We therefore investigated the role of TAFI in haemophilia A by measuring the clot lysis times of tissue factor induced fibrin formation and tPA mediated fibrinolysis. In haemophilia A plasma clot lysis times were normal at relatively high tissue factor concentrations but severely decreased at moderate to low tissue factor concentrations, indicating that the thrombin generation via the extrinsic pathway was insufficient to activate TAFI. Addition of factor VIII, TAFI or thrombomodulin restored the clot lysis times at low tissue factor concentrations. This confirms the hypothesis that the bleeding disorder in haemophilia A is not merely a defect in the initial clot formation but is in fact a triple defect: reduced thrombin formation via the extrinsic pathway at low tissue factor concentrations, a reduced secondary burst of thrombin generation via the intrinsic pathway and a defective down regulation of the fibrinolytic system by the intrinsic pathway.

Citing Articles

Mathematical modeling identifies clotting factor combinations that modify thrombin generation in normal and factor VIII-, IX-, or XI-deficient blood.

Stobb M, Neeves K, Monroe D, Sindi S, Leiderman K, Fogelson A Res Pract Thromb Haemost. 2024; 8(7):102570.

PMID: 39434958 PMC: 11491717. DOI: 10.1016/j.rpth.2024.102570.


Lipid nanoparticles and siRNA targeting plasminogen provide lasting inhibition of fibrinolysis in mouse and dog models of hemophilia A.

Strilchuk A, Hur W, Batty P, Sang Y, Abrahams S, Yong A Sci Transl Med. 2024; 16(735):eadh0027.

PMID: 38381848 PMC: 11293256. DOI: 10.1126/scitranslmed.adh0027.


Pharmacokinetic-Pharmacodynamic Modelling in Hemophilia A: Relating Thrombin and Plasmin Generation to Factor VIII Activity After Administration of a VWF/FVIII Concentrate.

Valke L, Cloesmeijer M, Mansouritorghabeh H, Barteling W, Blijlevens N, Cnossen M Eur J Drug Metab Pharmacokinet. 2024; 49(2):191-205.

PMID: 38367175 PMC: 10904421. DOI: 10.1007/s13318-024-00876-6.


Thrombotic Disease in Hemophilic Patients: Is This a Paradox in a State of Hypocoagulability?.

Badulescu O, Badescu M, Bararu Bojan I, Vladeanu M, Filip N, Dobreanu S Diagnostics (Basel). 2024; 14(3).

PMID: 38337802 PMC: 10854955. DOI: 10.3390/diagnostics14030286.


In patients with hemophilia, a decreased thrombin generation profile is associated with a severe bleeding phenotype.

Verhagen M, Heerde W, van der Bom J, Beckers E, Blijlevens N, Coppens M Res Pract Thromb Haemost. 2023; 7(2):100062.

PMID: 36865907 PMC: 9971314. DOI: 10.1016/j.rpth.2023.100062.